Specific post-marketing surveillance of Geninax(R) Tablets 200 mg Efficacy and safety against bacterial pneumonia - Specific post-marketing surveillance of Geninax(R) Tablets 200 mg Efficacy and safety against bacterial pneumonia

The safety in 730 patients and the efficacy in 535 patients were examined. The efficacy rate of garenoxacin for bacterial pneumonia was 92.8% (479/516 patients). The eradication rates for Streptococcus pneumoniae and Haemophilus influenzae, the major pathogens of bacterial pneumonia, were 98.5% (65/66 strains) and 100% (65/65 strains), respectively. The incidence of adverse drug reactions (including abnormal laboratory tests) was 7.9% (58/730 patients). Among the main adverse drug reactions, abnormal laboratory tests were observed in 2.1% patients (15/730), hepatobiliary disorders were observed in 1.8% patients (13/730), and skin and subcutaneous tissue disorders were observed in 1.6% patients (12/730).